Jian-Xing Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jian-Xing Ma has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Anthony Atala
Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27101, USA
2 shared publications - Yuanyuan Zhang
Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27101, USA
2 shared publications - Amish Asthana
Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA
1 shared publication - Andrew J. W. Huang
Department of Ophthalmology and Visual Sciences, Washington University in St. Louis (WashU), St. Louis, MO 63110, USA
1 shared publication - Daniella Beiner
Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA
1 shared publication Ehsan Kaffash
Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, USA
1 shared publication
Latest Publications
- Open Access
Advancing Precision Ophthalmology: Human Retinal Organoids as Platforms for Disease Modeling and Personalized Therapy
Human-induced pluripotent stem cell (hiPSC)-derived retinal organoids (ROs) have emerged as a transformative 3D in vitro model that closely recapitulates human retinogenesis and the layered cellular architecture of the native retina. This review highlights their profound utility as a precision platform for ophthalmic research. ROs, particularly those derived from patients with inherited retinal diseases (IRDs), provide an effective model for investigating disease pathogenesis, while retaining the patient’s genetic background. This specificity is crucial for the modeling of monogenic disorders like Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) and complex conditions like Age-Related Macular Degeneration (AMD), Diabetic Retinopathy (DR), and battle-related ocular trauma in the battlefield. Furthermore, ROs serve as a scalable and high-throughput tool for drug screening and toxicology testing, accelerating the identification of therapeutic compounds. Finally, they represent a renewable source for generating purified, functional retinal cells (e.g., photoreceptors and retinal ganglion cells) for precision cell therapies aimed at retinal repair. While challenges remain in achieving true vascularization and long-term maturation, RO technology is poised to rapidly advance personalized medicine and curative strategies for blinding retinal disorders.
Open AccessAdvancing Precision Ophthalmology: Human Retinal Organoids as Platforms for Disease Modeling and Personalized Therapy
Human-induced pluripotent stem cell (hiPSC)-derived retinal organoids (ROs) have emerged as a transformative 3D in vitro model that closely recapitulates human retinogenesis and the layered cellular architecture of the native retina. This review highlights their profound utility as a precision platform for ophthalmic research. ROs, particularly those derived from patients with inherited retinal diseases (IRDs), provide an effective model for investigating disease pathogenesis, while retaining the patient’s genetic background. This specificity is crucial for the modeling of monogenic disorders like Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) and complex conditions like Age-Related Macular Degeneration (AMD), Diabetic Retinopathy (DR), and battle-related ocular trauma in the battlefield. Furthermore, ROs serve as a scalable and high-throughput tool for drug screening and toxicology testing, accelerating the identification of therapeutic compounds. Finally, they represent a renewable source for generating purified, functional retinal cells (e.g., photoreceptors and retinal ganglion cells) for precision cell therapies aimed at retinal repair. While challenges remain in achieving true vascularization and long-term maturation, RO technology is poised to rapidly advance personalized medicine and curative strategies for blinding retinal disorders.
- Open Access
- 3 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9837
Restoring Bioenergetics in the Traumatized Eye: The Emergence of Mitochondrial Implantation as a Treatment for Acute Ocular Injury
Acute ocular injuries—such as chemical burns, ischemic insults, and mechanical trauma—frequently lead to irreversible vision loss by triggering rapid intracellular adenosine triphosphate (ATP) depletion, mitochondrial calcium overload, severe oxidative stress, and profound mitochondrial dysfunction. Current clinical management primarily focuses on suppressing inflammation and preventing secondary infection, but it fails to address the underlying bioenergetic collapse that drives cellular degeneration. While stem cell and extracellular vesicle therapies have been widely investigated, direct mitochondrial transplantation has recently emerged as a novel strategy for metabolic rescue. This review evaluates the therapeutic potential of exogenously administered mitochondria to mitigate mitochondrial dysfunction and acute trauma in the eye. Emerging preclinical studies demonstrate that transplanted mitochondria can be internalized by selected ocular cell types, conferring short-term cytoprotection, preserving retinal ganglion cell viability, and accelerating corneal epithelial repair. However, robust evidence regarding long-term mitochondrial integration, functional fusion, durable metabolic rescue, and clinical efficacy remains limited. Despite critical challenges in delivery, stability, and dosing, mitochondrial transplantation represents a promising frontier in regenerative ophthalmology that directly targets bioenergetic failure to preserve vision.
- 3 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9837
Open AccessRestoring Bioenergetics in the Traumatized Eye: The Emergence of Mitochondrial Implantation as a Treatment for Acute Ocular Injury
Acute ocular injuries—such as chemical burns, ischemic insults, and mechanical trauma—frequently lead to irreversible vision loss by triggering rapid intracellular adenosine triphosphate (ATP) depletion, mitochondrial calcium overload, severe oxidative stress, and profound mitochondrial dysfunction. Current clinical management primarily focuses on suppressing inflammation and preventing secondary infection, but it fails to address the underlying bioenergetic collapse that drives cellular degeneration. While stem cell and extracellular vesicle therapies have been widely investigated, direct mitochondrial transplantation has recently emerged as a novel strategy for metabolic rescue. This review evaluates the therapeutic potential of exogenously administered mitochondria to mitigate mitochondrial dysfunction and acute trauma in the eye. Emerging preclinical studies demonstrate that transplanted mitochondria can be internalized by selected ocular cell types, conferring short-term cytoprotection, preserving retinal ganglion cell viability, and accelerating corneal epithelial repair. However, robust evidence regarding long-term mitochondrial integration, functional fusion, durable metabolic rescue, and clinical efficacy remains limited. Despite critical challenges in delivery, stability, and dosing, mitochondrial transplantation represents a promising frontier in regenerative ophthalmology that directly targets bioenergetic failure to preserve vision.
- 23 January 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 391, 114656
Fenofibrate microemulsion eyedrops for treating nitrogen mustard induced corneal injury
- 23 January 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 391, 114656
Fenofibrate microemulsion eyedrops for treating nitrogen mustard induced corneal injury
- Open Access
- 2 January 2026
- Published by Elsevier in The American Journal of Pathology
- Vol. 196 (4) , 960-975
Peroxisome Proliferator-Activated Receptor α Deficiency Induces Vascular Pathologies through Endothelial Senescence in Diabetic Retinopathy
- 2 January 2026
- Published by Elsevier in The American Journal of Pathology
- Vol. 196 (4) , 960-975
Open AccessPeroxisome Proliferator-Activated Receptor α Deficiency Induces Vascular Pathologies through Endothelial Senescence in Diabetic Retinopathy